Privia Health Uses Kyruus’ Digital Patient Access Platform to Help Empower Consumers and Drive Practice Growth Boston, MA – October 5, 2021– Kyruus, the leader in provider search and scheduling solutions for healthcare organizations, today announced that Privia Health...
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – Seventh Approval Worldwide for QINLOCK and First European Approval – WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 12, 2021– Deciphera...
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell...
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain PenetrationOctober 7, 2021 at 9:00 AM EDT Currently enrolling APEX, a Phase 2 clinical study of bezuclastinib (CGT9486) for patients with...
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 – Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated...
DICE Therapeutics Announces Pricing of Upsized Initial Public Offering SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a...
Recent Comments